Not everyone should take B12
BPC-157 drives local angiogenesis (new blood vessel formation) through VEGF upregulation (Sikiric et al., Curr Pharm Des, 2018)
Two emerging pharmacological classes may challenge its risk-reward calculus: Oral GLP-1 agonists (e.g., oral semaglutide, danuglipron): These offer dosing convenience and eliminate injection site reactions, but bioavailability remains problematic (oral semaglutide achieves only 0.41% absorption, requiring daily dosing and strict administration protocols)
For rare ultra-sensitive cases, alternatives like acetic acid exist, but bacteriostatic water covers 90%+ of needs without complications
This is very important if youre taking many medications or have health issues
For subcutaneous injections, the best site is your upper arm